GB Sciences, Inc. (OTCMKTS:GBLX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersITEM 5.02 Departure of Officer and Director.
Effective May 8, 2017, Mr. Craig Ellins retired from the Company and in connection therewith, resigned his positions of Director and Chairman of the Board of Directors and his position of Chief Innovation Officer for the Company. John Poss, who replaced Mr. Ellins last year as CEO, will now also serve as Chairman of the Board.
Mr. Ellins was the visionary behind the Company’s focus on pharmaceutical grade, consistent and efficacious medicines as well as much of its proprietary technology designed to produce and enhance those medicines. Principal among these is the groundbreaking GB tissue propagation technique that allows for identical plants to be cultivated, as opposed to the traditional methods of generational growing where one plant is descended from its progenitor. The Company wishes Mr. Ellins all the best in his retirement.
PAGE
About GB Sciences, Inc. (OTCMKTS:GBLX)
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials. GB Sciences, Inc. (OTCMKTS:GBLX) Recent Trading Information
GB Sciences, Inc. (OTCMKTS:GBLX) closed its last trading session up +0.002 at 0.253 with 244,617 shares trading hands.
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials. GB Sciences, Inc. (OTCMKTS:GBLX) Recent Trading Information
GB Sciences, Inc. (OTCMKTS:GBLX) closed its last trading session up +0.002 at 0.253 with 244,617 shares trading hands.
